Open Access Open Access  Restricted Access Subscription Access

Wiskott–Aldrich Syndrome: A Rare X-Linked Immunodeficiency Disorder and Its Clinical Implications

Gayathri R.

Abstract


Thrombocytopenia, eczema, and recurring infections are the typical trifecta of Wiskott-Aldrich Syndrome (WAS), a rare X-linked recessive immunodeficiency condition. Due to abnormalities in the WAS gene, which produces the Wiskott–Aldrich Syndrome protein (WASP), which is essential for immune cell function, it mainly affects male children. Immune dysregulation, bleeding tendencies, and an increased vulnerability to infections and cancer are the outcomes of the syndrome. Improving survival and quality of life requires early diagnosis and effective treatment. While supportive therapies assist control symptoms and avoid problems, hematopoietic stem cell transplantation is thought to be the final treatment. This article examines Wiskott-Aldrich Syndrome's etiology, pathophysiology, clinical symptoms, diagnostic techniques, management modalities, and nursing implications.


Full Text:

PDF

References


Abbas, A. K., Lichtman, A. H., & Pillai, S. (2021). Basic immunology: Functions and disorders of the immune system (7th ed.). Elsevier.

Kliegman, R. M., St. Geme, J. W., Blum, N. J., Shah, S. S., Tasker, R. C., & Wilson, K. M. (2020). Nelson textbook of pediatrics (21st ed.). Elsevier.

Kumar, V., Abbas, A. K., & Aster, J. C. (2021). Robbins and Cotran pathologic basis of disease (10th ed.). Elsevier.

World Health Organization. (n.d.). Primary immunodeficiency disorders. World Health Organization.

National Institutes of Health. (n.d.). Wiskott–Aldrich syndrome overview. National Institutes of Health.

U.S. Food and Drug Administration. (2025, December 9). FDA approves first gene therapy treatment for Wiskott-Aldrich syndrome. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome

Wikipedia contributors. (2026). Etuvetidigene autotemcel. In Wikipedia, The Free Encyclopedia. Retrieved March 23, 2026, from https://en.wikipedia.org/wiki/Etuvetidigene_autotemcel

Note: While formatted correctly, Wikipedia is generally not recommended as a scholarly source. Consider citing primary literature if available.

Hacein-Bey-Abina, S., et al. (2022). Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott–Aldrich syndrome. Nature Medicine, 28(2), 285–292. https://doi.org/10.1038/s41591-021-01652-8

Aiuti, A., et al. (2017). Lentiviral hematopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: Interim results of a non-randomised, open-label, phase 1/2 clinical study. Blood, 130(10), 1115–1126. https://doi.org/10.1182/blood-2017-01-761643

de Mambro, L., & Sessa Stilhano, R. (2026). Advancements in gene therapy for Wiskott–Aldrich syndrome: From early trials to emerging approaches. International Journal of Hematology, 123(1), 9–23. https://doi.org/10.1007/s12185-025-03800-0

Buchbinder, D., Nugent, D. J., & Filipovich, A. H. (2014). Wiskott–Aldrich syndrome: Diagnosis, current management, and emerging treatments. The Application of Clinical Genetics, 7, 55–66. https://doi.org/10.2147/TACG.S39672


Refbacks

  • There are currently no refbacks.